JVJaap Vuyk

Jaap Vuyk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaap Vuyk has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drug distribution and elimination in anaesthetic practice

    by Eveline L. A. van Dorp, Douglas Eleveld, Erik Olofsen, Jaap Vuyk

    An understanding of pharmacokinetics is vital for the practice of anaesthesia. Drugs are, after administration, distributed throughout the body to the effect site (mostly the brain) to exert their effects. This can be influenced by differences in protein binding, systemic blood flow, and concomitant medication. Elimination of drugs from the body is through two main routes: either unchanged through the kidneys or through metabolism by the liver (and consecutive excretion through the kidneys). This process depends on the amount of hepatic blood flow and the amount of hepatic extraction. This in turn depends on the amount of protein binding and the intrinsic hepatic clearance. The cytochrome P450 enzyme family also plays an important role in drug elimination. Individual differences in enzyme activity can lead to differences in drug effect and clearances. Changes in enzyme activity by enzyme induction and inhibition can also be of influence on drug clearance. Compartmental, non-compartmental, and physiologically based models, and various statistical approaches to estimate these models, may be used to analyze the distribution and elimination of anaesthetic agents.

  • Mixed-Effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics

    by Jaap Vuyk, Bart Jan Lichtenbelt, Erik Olofsen, Jack W. van Kleef, Albert Dahan

    The combined administration of anesthetics has been associated with pharmacokinetic interactions that induce concentration changes of up to 30%. Midazolam is often used as a preoperative sedative in advance of a propofol-based anesthetic. In this study, we identified the influence of midazolam on the pharmacokinetics of propofol. Eight healthy male volunteers were studied on two occasions in a random crossover manner. During Session A, volunteers received propofol 1 mg/kg in 1 min followed by an infusion of 2.5 mg x kg(-1) x h(-1) for 59 min. During Session B, in addition to this propofol infusion scheme, a target-controlled infusion of midazolam (constant C(t): 125 ng/mL) was given from 15 min before the start until 6 h after termination of the propofol infusion. Arterial blood samples for blood propofol and plasma midazolam concentration analysis were taken until 6 h after termination of the propofol infusion. Nonlinear mixed-effects models examining the influence of midazolam and hemodynamic variables on propofol pharmacokinetics were constructed using Akaike criterion for model selection. In the presence of midazolam (C(blood): 224.8 +/- 41.6 ng/mL), the blood propofol concentration increased by 25.1% +/- 13.3% compared with when propofol was given as single drug. Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min. Inclusion of mean arterial blood pressure further improved the propofol pharmacokinetic model. Midazolam reduces the metabolic and rapid and slow distribution clearances of propofol. In addition, a reduction in mean arterial blood pressure is associated with propofol pharmacokinetic alterations that increase the blood propofol concentration.


  • Acetazolamide Improves Cerebral Oxygenation During Exercise at High Altitude

    by Jaap Vuyk, Jan Van Den Bos, Kees Terhell, Rene De Bos, Ad Vletter, Pierre Valk, Martie Van Beuzekom, Jack Van Kleef, Albert Dahan

    Vuyk, Jaap, Jan Van Den Bos, Kees Terhell, Rene De Bos, Ad Vletter, Pierre Valk, Martie Van Beuzekom, Jack Van Kleef, and Albert Dahan. Acetazolamide improves cerebral oxygenation during exercise at high altitude. High Alt. Med. Biol. 7:290–301, 2006.—Acute mountain sickness is thought to be triggered by cerebral hypoxemia and be prevented by acetazolamide (Actz). The effect of Actz on cerebral oxygenation at altitude remains unknown. In 16 members of the 2005 Dutch Cho Oyu (8201 m, Tibet) expedition, the influence of Actz and exercise (750 mg PO daily) on heart rate, peripheral and regional cerebral oxygen saturation (SaO2 and rSO2 ), the Lake Louise score (LLS), and psychomotor function were studied at 0 m 14 days prior to the expedition, after arrival at 3700 m on day 3, after arrival at 5700 m on day 29, and again at 5700 m before the end of the expedition on day 51. After arrival at 3700 m, the LLS of the climbers taking Actz (n = 8) was significantly lower compared to those who did not take Actz (n = 8): 0.75 ± 1.0 versus 2.9 ± 2.0, p < 0.05 (ANOVA). High LLSs were associated with low rSO2 values in rest and exercise (p < 0.01 and p < 0.001). With altitude, resting SaO2 and resting rSO2 decreased significantly (p < 0.001), irrespective of Actz use. Exercise at 3700 m and 5700 m reduced SaO2 and rSO2 even further compared to rest (p < 0.001), although at 3700 m the rSO2 was preserved better in those who took Actz (55.3 ± 4.3% versus 47.9 ± 5.7%, p < 0.05). Irrespective of Actz use, with altitude, the percentage of omissions in the vigilance and tracking test increased while the climbers' scores on vigor decreased (p < 0.05). In conclusion, at altitude, exercise-induced reduction in cerebral oxygenation is less in climbers on Actz compared to climbers not taking Actz. This effect is nullified after several weeks at altitude due to acclimatization in climbers not taking Actz.


  • Open Access

    Normal Bispectral Index Values in Healthy Volunteers

    by Jaap Vuyk, Bart-Jan Lichtenbelt, Albert Dahan, Frank H.M. Engbers, Anton G.L. Burm


    • 26 June 2004
      • Vol. 148  (26) , 1276-80

    [Bispectral analysis of the electroencephalogram: a new method for recording the level of consciousness during anaesthesia].

    by J Vuyk, E J R Egberink, A G L Burm

    Until recently, no measure was available that provided objective and reproducible information on the level of consciousness in patients under general anaesthesia. Several decades of research to find a reliable measure for determining the depth of anaesthesia has now led to the clinical introduction of the bispectral index scale (BIS), a parameter derived from the electroencephalogram. Implementation of the BIS-monitor in anaesthetic practice leads to a reduced use of hypnotic agents, a more rapid recovery phase and possibly a reduced incidence of awareness.


  • Strategies to Optimise Propofol-Opioid Anaesthesia

    by Bart-Jan Lichtenbelt, Martijn Mertens, Jaap Vuyk

    Propofol-opioid combinations are widely used in today’s anaesthetic practice. Over the past 20–30 years the pharmacology of these agents has been described in increasingly greater detail. Together with novel intravenous administration devices and improved anaesthetic depth monitoring, this has created a basis for the optimisation of the administration of propofol-opioid anaesthesia. This article describes the current strategies regarding the application of this type of anaesthesia, focusing on three strategic tools: (i) application of pharmacokinetic-pharmacodynamic knowledge of propofol and the Opioids, with particular attention to pharmacodynamic interactions between them; (ii) the use of state-of-the-art administration techniques; and (iii) the application of bispectral index monitoring. Together, these techniques have improved the level of control, the flexibility and the safety of anaesthetic practice.


    • 1 January 2001
      • Vol. 52  (4) , 445-51

    Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions.

    by J Vuyk

    This manuscript describes the pharmacokinetic and pharmacodynamic interactions between propofol and the opioids. In vitro studies describe the reduced clearance of opioids in the presence of propofol, midazolam and etomidate due to interaction at the cytochrome P450 enzyme system. In vivo, however, pharmacokinetic interaction studies by mixed effects modelling predominantly focus on haemodynamic factors affecting distribution and elimination of concomitantly administered agents. In the presence of propofol the elimination clearance and rapid and slow distribution clearance of alfentanil is decreased. Consequently, plasma alfentanil concentrations are increased in the presence of propofol. Vice versa alfentanil reduces propofol elimination clearance and increases the deep volume of distribution. Propofol and the opioids interact in a synergistic manner for various clinical end points. The magnitude of interaction is similar between the various opioids and hypnotic agents, taken into consideration the differences in potency between the opioids. A. Speed of induction. Using PK/PD interaction data speed of induction can be optimised. Of importance are the magnitude of PD interaction between propofol and the various opioids, the rate of administration and the time to peak effect of the agents involved. B. Haemodynamic stability. In ASA 1-2 patients the opioid induced hypnotic dose reduction is not associated with an increased haemodynamic stability of induction of loss of consciousness. In elderly patients or patients known with cardiovascular instability high opioid-low propofol anaesthesia may be associated with improved haemodynamic stability during induction of anaesthesia, however, no data are available regarding this yet. C. Speed of recovery. Time to return of consciousness after termination of propofol-opioid infusions of various duration can be reduced using optimal propofol-opioid concentrations. In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil. D. Spontaneous respiration. For single agents some data allow proper targeting of a drug concentration that is associated with adequate intraoperative respiration. However, no data exist on drug interactions regarding the respiratory depressant effects of hypnotic-opioid combinations. The proper exploration and use of published pharmacokinetic and pharmacodynamic interaction data allows the clinical anaesthesiologist to optimise the clinical administration of propofol and the various opioids when given alone or in combination.